phrykt

Axogen, Inc. (AXGN): who owns it and who trades it

As of Nov 16, 2026, AXGN insiders reported 34 open-market sales worth $17.1M and no purchases in the last 12 months, with 27% of the sale value made under pre-set 10b5-1 plans. The largest seller was Marc A Began (Vice president), with $3.9M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Axogen

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns AXGN

253 funds and institutions reported AXGN shares worth $2.5B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 8.3%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.8.3%
First Light Asset Management, LLC5.2%
Morgan Stanley5.2%
California State Teachers Retirement System5.0%
Vanguard Capital Management LLC4.2%
Assenagon Asset Management S.A.3.9%
Polar Capital Holdings Plc2.8%
Artemis Investment Management LLP2.6%
Wellington Management Group LLP2.6%
Geode Capital Management, LLC2.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.4.42M8.31%$204M+14%
First Light Asset Management, LLC2.75M5.17%$127M-31%
Morgan Stanley2.75M5.17%$127M-12%
California State Teachers Retirement System2.66M5.00%$57.6M+4400%
Vanguard Capital Management LLC2.26M4.25%$104M-1%
Assenagon Asset Management S.A.2.09M3.93%$96.4M+51%
Polar Capital Holdings Plc1.50M2.82%$69.3MNo change
Artemis Investment Management LLP1.40M2.63%$64.5M+299%
Wellington Management Group LLP1.39M2.62%$64.3M+44%
Geode Capital Management, LLC1.38M2.59%$63.5M+13%
Citadel Advisors LLC1.36M2.56%$62.9M+455%
Wasatch Advisors LP1.30M2.44%$59.9M-30%
Goldman Sachs Group Inc1.26M2.37%$58.3M+116%
State Street Corp1.25M2.34%$57.6M+9%
FMR LLC (Fidelity)1.22M2.30%$56.5M-7%
Hood River Capital Management LLC1.07M2.01%$49.3M–
T. Rowe Price Associates1.02M1.91%$47M+1905%
Rtw Investments, LP1.01M1.90%$46.7M–
Next Century Growth Investors LLC872,5461.64%$40.3M+1%
UBS Group AG836,2091.57%$38.6M+632%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, AXGN insiders reported $0 of open-market purchases and $17.1M of sales. 27% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$17.1M
34 trades, 11 people
Sales under a 10b5-1 plan
27%
Share of sale value
Latest trade
Sep 2, 2026
Filed Sep 4, 2026

Purchases and sales by month

$10.6M$10.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 2, 2026Joseph A. TyndallDirectorSale plan3,500$49.70$174KForm 4
Aug 11, 2026Amy McBride WendellDirectorSale plan13,353$48.42$647KForm 4
Aug 10, 2026Marc A BeganVice presidentSale plan67,500$47.35$3.2MForm 4
Aug 7, 2026Kathy Johnson WeilerDirectorSale plan14,150$45.30$641KForm 4
May 8, 2026Amy McBride WendellDirectorSale1,647$42.60$70.2KForm 4
May 7, 2026John JohnsonDirectorSale11,050$43.26$478KForm 4
May 7, 2026Kathy Johnson WeilerDirectorSale16,344$44.09$721KForm 4
May 7, 2026Jens KempChief Marketing OfficerSale4,000$43.44$174KForm 4
May 7, 2026Lindsey Marie HartleyCFOSale478$43.67$20.9KForm 4
May 7, 2026Lindsey Marie HartleyCFOSale573$43.67$25KForm 4
May 7, 2026Doris QuackenbushVice presidentSale3,878$43.51$169KForm 4
Mar 16, 2026Erick Wayne DeVinneyChief Innovation OfficerSale5,221$32.84$171KForm 4
Dec 16, 2025Amy McBride WendellDirectorSale18,248$29.31$535KForm 4
Dec 16, 2025Amy McBride WendellDirectorSale5,000$29.31$147KForm 4
Dec 16, 2025Amy McBride WendellDirectorSale20,436$29.31$599KForm 4
Dec 16, 2025Kathy Johnson WeilerDirectorSale6,580$29.55$194KForm 4
Dec 16, 2025Kathy Johnson WeilerDirectorSale18,248$29.55$539KForm 4
Dec 16, 2025Kathy Johnson WeilerDirectorSale21,825$29.55$645KForm 4
Dec 15, 2025Lindsey Marie HartleyCFOSale14,812$29.86$442KForm 4
Dec 11, 2025Marc A BeganVice presidentSale13,222$30.00$397KForm 4
Dec 10, 2025Michael D DaleCEOSale25,000$30.00$750KForm 4
Dec 9, 2025Michael D DaleCEOSale61,463$31.21$1.9MForm 4
Dec 9, 2025Joseph A. TyndallDirectorSale10,860$30.98$336KForm 4
Dec 9, 2025Joseph A. TyndallDirectorSale14,248$30.98$441KForm 4
Dec 9, 2025Erick Wayne DeVinneyChief Innovation OfficerSale19,517$31.21$609KForm 4
Dec 9, 2025Jens KempChief Marketing OfficerSale8,156$31.21$255KForm 4
Dec 9, 2025Marc A BeganVice presidentSale9,278$31.21$290KForm 4
Dec 9, 2025Paul ThomasDirectorSale21,399$29.61$634KForm 4
Dec 9, 2025John JohnsonDirectorSale8,545$29.98$256KForm 4
Dec 9, 2025John JohnsonDirectorSale13,141$29.98$394KForm 4
Dec 8, 2025John JohnsonDirectorSale11,891$31.22$371KForm 4
Dec 8, 2025John JohnsonDirectorSale11,802$31.26$369KForm 4
Dec 8, 2025Lindsey Marie HartleyCFOSale11,533$31.56$364KForm 4
Dec 8, 2025Lindsey Marie HartleyCFOSale2,854$31.56$90.1KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Marc A BeganEVP & General Counsel–$3.9MAug 10, 2026
Kathy Johnson WeilerDirector–$2.7MAug 7, 2026
Michael D DaleChief Executive Officer–$2.7MDec 10, 2025
Amy McBride WendellDirector–$2MAug 11, 2026
John JohnsonDirector–$1.9MMay 7, 2026
Joseph A. TyndallDirector–$952KSep 2, 2026
Lindsey Marie HartleyCFO–$942KMay 7, 2026
Erick Wayne DeVinneyChief Innovation Officer–$781KMar 16, 2026
Paul ThomasDirector–$634KDec 9, 2025
Jens KempChief Marketing Officer–$428KMay 7, 2026
Doris QuackenbushSales VP–$169KMay 7, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AXGN short interest

High short interest. 11.7% of AXGN shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went up 118%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 6.99M AXGN shares were sold short, 11.7% of the shares outstanding, up 36.5% from the report before. At the average daily volume of 2.13M shares, buying them all back would take about 3.3 trading days (days to cover).

Shares short, % of all shares

11.7%May 15Oct 3012.6%

Days to cover

3.3May 15Oct 304.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20266.99M11.71%+36%2.13M3.3
Oct 15, 20265.12M9.53%+9%1.69M3.0
Sep 30, 20264.70M8.74%+16%1.13M4.2
Sep 15, 20264.06M7.54%+6%1.42M2.9
Aug 31, 20263.81M7.09%+13%903,1674.2
Aug 14, 20263.37M6.26%-17%826,5544.1
Jul 31, 20264.07M7.57%-25%1.22M3.4
Jul 15, 20265.44M10.24%+17%1.50M3.6
Jun 30, 20264.63M8.72%+27%1.63M2.9
Jun 15, 20263.66M6.89%+9%1.22M3.0
May 29, 20263.37M6.34%+5%811,5494.2
May 15, 20263.20M6.02%-6%786,6984.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Axogen company events

Axogen filed 13 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026AnnouncementShared information with investors. Filing
  2. Oct 28, 2026ResultsReleased financial results. Filing
  3. Oct 1, 2026AnnouncementShared information with investors. Filing
  4. Sep 10, 2026AgreementAmended an earlier report. Of the Original Form 8-K as Exhibit 2.1 and (ii) furnish a corrected version of the investor presentation previously furnished as Exhibit 99.2 to the Original Form 8-K. Except as set forth herein, the Original Form 8-K remains unchanged. Filing
  5. Sep 10, 2026AgreementAxogen, Inc., a Minnesota corporation, entered into an Agreement and Plan of Merger with Omega Merger Sub, Inc., a Georgia corporation and wholly owned subsidiary of the Company, BioCircuit Technologies, Inc., a Georgia corporation, and Michelle Jarrard, solely as representative of BioCircuit’s… Filing
  6. Jul 29, 2026ResultsReleased financial results. Filing
  7. Jun 23, 2026VoteReported shareholder vote results. Filing
  8. Apr 28, 2026ResultsReleased financial results. Filing
  9. Feb 24, 2026ResultsReleased financial results. Filing
  10. Jan 23, 2026AgreementAxogen, Inc. entered into an underwriting agreement with Wells Fargo Securities, LLC and Mizuho Securities USA LLC, as representatives of the underwriters. Filing
  11. Jan 12, 2026ResultsReleased financial results. Filing
  12. Dec 5, 2025LeadershipThe Compensation Committee of the Board of Directors of Axogen, Inc. approved amendments to the compensation arrangements for Lindsey Hartley, the Company’s Chief Financial Officer. Filing
  13. Dec 4, 2025AnnouncementThe Company announced it received FDA approval of its Biologics License Application for Avance ® (acellular nerve allograft-arwx). Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Axogen financials

Famous investors that hold AXGN

4 of the 50 well-known investors we track reported holding AXGN in their latest 13F filing. The largest position is Steve Cohen's, worth $16.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 2026393,903$16.5M0.0%+75%
Israel Englander · Millennium ManagementQ3 2026154,404$6.5M0.0%+467%
Ken Griffin · Citadel AdvisorsQ3 202630,524$1.3M0.0%-98%
Jim Simons · Renaissance TechnologiesQ3 202618,831$789K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named AXGN in the last 120 days.

FiledHolderFormStake
Nov 13, 2026Morgan Stanley13G/A2.8%
Nov 13, 2026Morgan Stanley13G/A2.8%
Oct 2, 2026Divisadero Street Capital Management, LP13G6.8%
Oct 2, 2026Divisadero Street Capital Management, LP13G6.8%

Questions about Axogen, Inc. (AXGN) stock

Who owns the most AXGN stock?

The largest reported owner of Axogen, Inc. (AXGN) is BlackRock, Inc., with 8.3% of the company. In total, 253 funds and institutions reported holding AXGN at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are AXGN insiders buying or selling?

In the last 12 months, AXGN insiders reported no open-market purchases and 34 sales worth $17.1M. The latest trade was on Sep 2, 2026. See every trade.

What is the short interest in AXGN?

As of Oct 30, 2026, 6.99M AXGN shares were sold short, 11.7% of the shares outstanding, up 36.5% from the report before. At the average daily volume of 2.13M shares, buying them all back would take about 3.3 trading days (days to cover). See the history.

Which famous investors hold AXGN?

4 of the 50 well-known investors we track reported AXGN in their latest 13F filing, including Steve Cohen, Israel Englander, Ken Griffin. The largest position is worth $16.5M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.